Betathine

(redirected from Beta LT)

Betathine

A low-molecular-weight disulfide orphan agent which made it to clinical trials for treating myeloma, low-grade B-cell lymphoma, and metastatic melanoma. Its development was abandoned in 1999.
References in periodicals archive ?
4-1BBL, 506U78, Actimmune, Ad-IFNg, AlloMune, AMD-3100, Aplidin, ASIbcl, Atragen, Avastin, BCX1777, B-E8, Beta LT, Bexxar, Caelyx, Calsed, Campath, Clofarabine, CMC-544, CpG-7909, Depocyte, Edodekin Alpha, Elsamitrucin, FAVID, Fludara, FR-901228, Ganite, GEMZAR, GENASENSE, GRN163, GTI-2040, GTOP-99, hA20, HMR1275, HSPPC-96, Hu1D10, hum291, HuMax, IDEC-114, IDEC-152, IDIOVAX, Intron A, INX-3280, ISF-154, KiroMAb, LY317615, Lymphocide, Lymphorad131, MDX-060, MGV, Midostaurin, MT103, NIPENT, NOVATRONE, Oncolym, OncoTCS, Ontak, Orathecin Rubitecan, Parlodel, PEGIntron, Porleukin, Pretarget Lymphoma, PRO64553, Product R, Prothecan, Remitogen, Rituxan, SGN-30, SGN-35, T-900607, TH9402, Thalidomid, Trap, TRISENOX, UCN-01, VAXID, VB2-011, VEGF Trap, VELCADE, Zevalin
Head, Clinical Research Unit and Principal Investigator of its Beta LT (TM) clinical trials at McGill University/Jewish General Hospital will be presenting in Orlando, Florida at the prestigious annual meeting of the American Society of Hematology (ASH) on Saturday, December 8, 2001 entitled "Beta-Alethine Phase I/II Data: Immune Stimulation in Patients with Follicular Lymphoma and Myeloma with Evidence of Tumor Response and No Significant Toxicity.
the Canadian trial CT scans documented shrinkage in cancers one hundred million times that size following single agent therapy with the Beta LT.
While most drugs have a single application, the fact that Beta LT has a line up of potential applications increases both market size and dramatically decreases investor risk," says Lance Hoboy, LifeTime's Executive Vice President.
For more information about Beta LT or LifeTime, please contact Char Tara Albert at 301-405-0608.
Beta LT is a new anti-cancer agent designed to stimulate the immune system and therefore have an anti-cancer effect.
Evidence of a biological effect was also sought in the Beta LT Phase I/II trials.
In the Beta LT trial, even patients in the late stage of the disease and with massive tumors, who failed chemotherapy multiple times, are not only eligible but have had tumor reduction while being treated with Beta LT.
Data to date indicate Beta LT at this dose is non-toxic, increases surface TNF, and can have anti-lymphoma effects," reports Dr.
The first myeloma patient treated has been receiving Beta LT for 9 weeks.
No side effects have been reported from either initial or repeated Beta LT administration.
Most importantly, preliminary data, while requiring verification, controls and repetition in other patients, is consistent with Beta LT having effects on certain immune parameters and on the levels of protein produced by the cancer cells," he continues.